alexa Evaluation of DNA Methylation of MAP9 Gene in Breast Ca

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker

Mina Dehbid1*, Seyed Ahmad Aleyasin1 and Hamidreza Vaziri2

1Medical Biotechnology Division, National Institute of Genetic Engineering and Biotechnology (NIGEB), Iran

2The University of Guilan, Rash, Guilan, Iran

*Corresponding Author:
Mina Dehbid, M.Sc
The National Institute of Genetic Engineering and Biotechnology
Shahrak-e Pajoohesh, km 15, Tehran - Karaj Highway
Tehran, Iran, P.O. Box: 14965/161, Tehran, Iran
Tel: (+98) 21 44787301-27 (+98) 21 44787396, 98
Fax: (+98) 21 44787399
E-mail: [email protected]

Received date: December 31, 2015; Accepted date: January 28, 2016; Published date: January 30, 2016

Citation: Dehbid M, Aleyasin SA, Vaziri H (2016) Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker. J Mol Biomarkers Diagn S8:015. doi:10.4172/2155-9929.S8-015

Copyright: © 2016 Mina Dehbid, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: Recent findings indicate epigenetic modifications as key factors in breast carcinogenesis. The abnormal methylation patterns of genes are among the consequences of epigenetic changes. The DNA methylation is involved in the regulation of gene activity and abnormal DNA methylation is associated with various diseases, including cancer. Due to the importance of epigenetics in cancer, particularly breast cancer, it seems to perform the most effective methods of prediction, detection and tracking of recurrence, and the availability of suitable biomarkers. In this study, the MAP9 (Microtubule-Associated Protein 9) gene methylation was examined as an epigenetic biomarker of cancer.

Methods: We evaluated 30 breast cancer samples and 30 normal samples to identify diagnosis biomarkers for breast cancer. Sample of breast cancers were identified, with different Clinical and pathological data, which might be related with changes in MAP9 gene methylation. DNA was extracted from whole blood of breast cancer patients and healthy samples. The methylation-sensitive restriction enzymes were used to identify methylated site in epigenetic marker. Methylation-sensitive enzyme cannot cut hypermethylated sequences. Methylation-sensitive enzyme is not capable of cutting sequences of MAP9 gene, thus replication occurs.

Results: MAP9 gene is significantly hypermethylated in breast cancer (P<0.05). Moreover the results of this study indicated that there was no relation between stage of disease, age of patients, Estrogen Receptor (ER), Progesterone Receptor (PR), and human epidermal growth factor 2 (HER2) status and the methylation of MAP9 gene in breast cancer samples (P>0.05).

Conclusion: In this study indicated MAP9 gene methylation changes in breast cancer and it can be used as molecular biomarker for breast cancer diagnosis.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version